MAPT and Alzheimer disease: Encouraging results in a mouse model of tauopathy, in which salsalate decreased acetylation of tau protein, rescued tau turnover and ameliorated cognitive performance (Min et al., 2015), led to the initiation of a phase 1b 12-month, randomized, double-blind, placebo-controlled study (NCT03277573), in patients with mild to moderate AD, investigating safety and tolerability as primary endpoint and, among others, measurements in blood and CSF salsalate and changes in CSF biomarkers and cognition as secondary and exploratory endpoints, respectively.